What is the Purpose of this Study?
Objectives Primary To characterize the safety and tolerability of TEV-56278 in the trial population To determine a RP2D Secondary To characterize the serum pharmacokinetics of TEV-56278 in the trial population To evaluate the antitumor activity of TEV-56278 in the trial population
Eligibility
- * Have an established histological diagnosis of selected solid tumor and must have received and progressed on established standard therapies or have been intolerant to such therapy or have been considered by the Investigator as ineligible for approved standard therapy
- * Have a life expectancy≥12 weeks at the time of the screening
- * Women of childbearing potential must agree to use highly effective methods of contraception for the course of the trial through 120 days after the last dose of trial medication
- * Males who are sexually active with women of childbearing potential must agree to use condoms and refrain from donating sperm for the course of the trial through 120 days after the last dose of trial medication
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute : Crystal Ducharme
More about this Clinical Trial
What is the full name of this clinical trial?
TV56278-ONC-10203: A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors